europe non small cell lung cancer treatments market 2010 2020 brochure

Eu ro p e N o n - S m a l l Ce l l L u n g C a n c e r Tre a t m e n t s M a rke t O p p o r t u n i t ie s , 2 0 1 0 - 2 0 2 0

P h a r m a & H e a l t h c a r e C o n s u l t a n t s

2

© Pharmaion

N o n - S m a l l C e l l L u n g C a n c e r T r e a t m e n t s O v e r v i e w

Squamous Cell Carcinoma

Adenocarcinoma

Large Cell Carcinoma

Non-Small Cell Lung Cancer

A malignant disease in which cancer cells grow and proliferate inside the lungs

Squamous Cell Carcinoma

AdenocarcinomaLarge Cell Carcinoma

Others

Also known as epidermoid

carcinoma, cancer calls are formed

inside airways of the lung; accounts for X% of total lung cancer cases in

Europe

Most common type of lung cancer which

develops in the mucous secretion cells (Phlegm);

accounts for X% of total lung cancer cases in Europe

Cancer cells usually develops in the

lining of alveoli that secretes mucous,

accounts for X% of total lung cancer cases in Europe

Others include carcinoid tumor,salivary gland

tumour, sarcomatoid

carcinoma, etc.

Non-Squamous Cell Carcinoma

3

© Pharmaion

T a b l e o f C o n t e n t s

S No. Contents

1. Non-Small Cell Cancer Treatments Overview

2. Research Methodology

3. Analyst View

4. Global Non-Small Cell Lung Cancer Treatments Market Overview

5. Europe Lung Cancer Epidemiology

6. Europe Non-Small Cell Lung Cancer Treatments Market Overview

7. Europe Non-Small Cell Lung Cancer Treatments Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Target Disease

7.2.2. By Type

7.2.3. By Country

7.2.4. By Company

8. Europe Non-Small Cell Lung Cancer Treatments Regional Market Outlook

8.1. Germany Non-Small Cell Lung Cancer Treatments Market Analysis

8.1.1. Market Size & Forecast

8.1.1.1. By Value

8.1.2. Market Share & Forecast

8.1.2.1. By Type

8.2. France Non-Small Cell Lung Cancer Treatments Markets Analysis


8.2.1.1. By Value

4

© Pharmaion


S No. Contents


8.2.2.1. By Type

8.3. Spain Non-Small Cell Lung Cancer Treatments Market Analysis


8.3.1.1. By Value


8.3.2.1. By Type

8.4. Italy Non-Small Cell Lung Cancer Treatments Market Analysis


8.4.1.1 By Value


8.4.2.1. By Type

8.5. United Kingdom Non-Small Cell Lung Cancer Treatments Market Analysis


8.5.1.1. By Value


8.5.2.1. By Type

9. Europe Non-Small Cell Lung Cancer Treatments Segmental Market Outlook

9.1. Europe NSCLC Chemotherapy Market Outlook


9.1.1.1. By Value


9.1.2.1. By Type

5

© Pharmaion


S No. Contents

9.2. Europe NSCLC Surgery Market Outlook


9.2.1.1. By Value


12.2.1 By Type

9.3. Europe NSCLC Radiotherapy Market Outlook


9.3.1.1. By Value


9.3.1.1 By Type

9.4. Europe Target Therapy Market Outlook


9.4.1.1 By Value


9.4.2.1. By Type

10. Market Dynamics

15.1. Drivers

15.2. Challenges

11. Market Trends & Developments

11.1. Development of New Therapeutics in Immunotherapy

11.2. Video Assisted Thoracic Surgery

11.3. Photodynamic Therapy (PDT)

11.4. Laser Therapy

6

© Pharmaion


S No. Contents

11.5. Biomarker

12. Policy & Regulatory Landscape

13. Europe NSCLC Product Roadmap

14. Competitive Landscape

14.1 Company Profiles

14.1.1. Roche Holding AG

14.1.2 Eli Lilly and Company Limited

14.1.3 Boehringer Ingelheim GmbH

14.1.4 Pfizer AG

14.1.5 AstraZeneca

14.1.6 Celgene International Sárl

14.1.7 Bristol-Myers Squibb

14.1.8 Merck Sharp & Dohme Limited

14.1.9 Novartis AG.

14.1.10 Teva Pharmachemie

15. Strategic Recommendations

16. About Us & Disclaimer

7

© Pharmaion

R e s e a r c h M e t h o d o l o g y

Primary Research

•Identifying Key Opinion Leaders

•Questionnaire Design

•In-depth Interviews

•Coverage across Value Chain market

Market Estimation & Forecasting

Top-down approach for Market size estimation

Historical trend examination

Impact analysis of drivers and challenges to market growth

Statistical evaluation to develop the actual forecast

Data Validation, Analysis and Interpretation

Data validation through Primary & Secondary outreach, data analysis and interpretation of key findings

Preliminary Data Mining

Qualitative and Quantitative research

2015E 2016F 2017F 2018F 2019F 2020F

CAGR (2015E-2020F): XX%

Europe Non- Small Cell Lung Cancer Treatments Market Opportunities,

2020

Secondary Research

•Government Websites

•Company Annual Reports

•White Papers

•Investor Presentation

•Financial Reports

8

© Pharmaion


Baseline Methodology:

For the study of the Europe non-small cell lung cancer treatments market, Pharmaion has gathered

information through an exhaustive search of credible databases prudently evaluated all the collected

information and presented it in the most accurate and detailed manner.

Primary Sources

Key Stakeholders:

Product/Brand Managers

Business Development

Managers

Regional Mangers

Regulatory Affairs Personnel

Marketing & Sales Managers

Head of Patient Support

Programme

Substantial data points for analysis, interpretation and market size estimation

Data Triangulation

(Data validation

through cross verification

from primary & secondary

sources)

Qualitative and quantitative data from company

website, financial reports, research articles, designed

questionnaires etc.

In-depth interviews of key stakeholders of

major companies

Secondary Sources

Analysis of Data from credible sources: EUCAN Globocan ESMO EMA

9

© Pharmaion


Europe Non- Small Cell Lung Cancer Treatments Market - Market Size Estimation

Europe non-small cell lung cancer (NSCLC ) treatments market has been segmented into twocategories: squamous NSCLC and non-squamous NSCLC

On the basis of therapy, the market has been further into four categories, namely, surgery,radiotherapy, chemotherapy and target therapy.

Country-wise, the market has been further segmented into Germany, France, Italy, Spain, UK, and Restof the Europe.

Estimation of Europe Non- Small Cell Lung Cancer Treatments

Market Size

To

p-d

ow

n A

pp

ro

ach

Calculation of Sub-

segment market size

Sub-Segment Market Size Calculation

Sub-segment Market Share (From

Primary And Secondary

Research) XSegment Market

Value

10

© Pharmaion

I n d u s t r y B r i e f

Europe Non-Small Cell Lung Cancer Treatments Market to Cross US$ 3 billion by 2019

According to recently published Pharmaion report, “Europe Non-Small Cell Lung Cancer Treatments MarketOpportunities, 2010 - 2020”, the non-small cell lung cancer (NSCLC) treatments market in Europe is anticipated to crossUS$ 3 billion by 2019. Growth in the market is anticipated on account of increasing NSCLC prevalence rate, continuousexposure to radiation and carcinogens andgrowing patient awareness. Moreover, late appearance of disease symptomsleads to delay in diagnosis and advancement in the cancer stage, which results in increasing the cost of the treatment,and thereby generate higher revenues for Europe NSCLC treatments market.

In Europe, majority of the lung cancer patients were found to be suffering from NSCLC in 2014, and the trend isanticipated to continue through 2020. With increasing prevalence of NSCLC among European citizens, the demand forthe treatments and therapies is forecast to grow at a robust pace in the next five years. Moreover, anticipated launch ofmultiple drugs across different classes of therapies is further anticipated to aid the non-small cell lung cancer treatmentsmarket in Europe during 2015 – 2020. However, patent expiration of drug and increasing availability of generic medicineare posing a challenge to the NSCLC treatments market in Europe.

On the basis of therapy offered, the market has been segmented into four broad categories, namely, chemotherapy,radiotherapy, surgery and target therapy. Among these categories, chemotherapy segment dominated the Europe non-small cell lung cancer treatments market in 2014. With various number of new drug entrants, coupled with numerousclinical trials in pipeline, the segment is anticipated to continue its dominance in the Europe NSCLC treatments marketthrough 2020. Country-wise, the largest share in Europe’s NSCLC treatments market was captured by Germany, followedby France, Italy, Spain and the UK.

“Europe non-small cell lung cancer treatments market will continue to exhibit promising growth over the next five years.Innovation and new product launches by the existing as well as the new market players is the major factor anticipated todrive non-small cell lung cancer treatments market during the forecast period. Moreover, growing adoption of VideoAssisted Thoracic Surgery, Photodynamic Therapy and Laser Therapy, coupled with increasing applications of monoclonalantibodies and immunotherapy are among the major factors driving Europe non-small cell lung cancer treatmentsmarket.” said Mr. Karan Chechi, Research Director with Pharmaion, a research based global pharmaceutical andhealthcare consulting firm.

http://www.pharmaion.com/report/europe-non-small-cell-lung-cancer-treatments-market-opportunities-2010--2020/31.html


11

© Pharmaion

1 2 3 4 57 8 9 10 11 12

2010 2011 2012 2013 2014 2015E 2016F 2017F 2018F 2019F 2020F

Europe Non-Small Cell Lung Cancer Treatments

Market Size, By Value, 2010-2020F (USD Million)

S a m p l e D a t a - S n a p s h o t

Europe Non-Small Cell Lung Cancer Treatments Market, By

Target Disease, By Value, 2010-2020F

16.00%16.01%16.02%16.03%16.04%16.05%16.06%16.07%16.08%16.09%16.10%

70.00%70.01%70.02%70.03%70.04%70.05%70.06%70.07%70.08%70.09%70.10%

2010 2011 2012 2013 2014 2015E 2016F 2017F 2018F 2019F 2020F

Squamous NSCLC Non-Squamous NSCLC


Market Share, By Company, By Value, 2010-2020F

Roche, 20.00%

Eli Lilly, 20.00%

Astra Zeneca PLC, 20.00%

Pfizer, 20.00%

Others, 20.00% Roche,

20.00%

Eli Lilly, 20.00%

Astra Zeneca PLC, 20.00%

Pfizer, 20.00%

Others, 20.00%

Europe Non-Small Cell Lung Cancer Target Therapy

Market Share, By Type, By Value, 2014 & 2020F

MABs + Gene Therapy, 50%

Others, 50%

MABs + Gene Therapy, 50.00%

Others, 50.00%


Market Share, By Country, By Value, 2010-2020F

8.00% 8.01% 8.02% 8.03% 8.04% 8.05% 8.06% 8.07% 8.08% 8.09% 8.10%

9.00% 9.01% 9.02% 9.03% 9.04% 9.05% 9.06% 9.07% 9.08% 9.09% 9.10%

10.00% 10.01% 10.02% 10.03% 10.04% 10.05% 10.06% 10.07% 10.08% 10.09% 10.10%

11.00% 11.01% 11.02% 11.03% 11.04% 11.05% 11.06% 11.07% 11.08% 11.09% 11.10%

13.00% 13.01% 13.02% 13.03% 13.04% 13.05% 13.06% 13.07% 13.08% 13.09% 13.10%

30.00% 30.01% 30.02% 30.03% 30.04% 30.05% 30.06% 30.07% 30.08% 30.09% 30.10%

2010 2011 2012 2013 2014 2015E 2016F 2017F 2018F 2019F 2020F

UK Spain Italy

France Germany Rest of the Europe

Male Female

1

2

5

6

2012 2015

Europe Lung Cancer

Incidences, By Gender, 2012 &

2015E

Male Female

910

1314

2012 2015

Europe Number of Deaths due to

Lung Cancer, By Gender, 2012 &

2015E

R e p o r t O r d e r i n g

To View Sample OR Purchase Report

Report Price

Report Name: Europe Non-Small Cell Lung Cancer Treatments

Market Opportunities, 2010-2020

License Type Price

Single User License $3000

Single User License Print $3500

Enterprise License $7000

12



13

© Pharmaion

A b o u t U s & D i s c l a i m e r

NORTH AMERICA

Pharmaion Consultants LLC

708 3RD Avenue, 6th Floor, New York, NY,

United State, 10017

[email protected]

+1 646 360 1656

www.pharmaion.com

About Us

Pharmaion is a research based management consulting firm focused exclusively on Healthcare & Pharmaceutical industry.

Pharmaion’s core values are value, integrity and insight. Led by a team of dynamic industry experts, Pharmaion provides itscustomers with high value market research and advisory services that helps them identify new market opportunities, growthengines and innovative ways to capture the market share. As a result, Pharmaion’s clients lead rather than follow markettrends. Not bound by legacy, Pharmaion’s cutting-edge research model leverages its decades of research knowledge and anincreased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditionalmarket research, Pharmaion’s reports do not just deliver data and knowledge rather highlights the insights in a more usable andinteractive format for its clients.

Pharmaion is committed to assisting customers worldwide with their unique market research needs by providing them withcomprehensive, value-added solutions and professional market intelligence services. Pharmaion employs the industry’s best-trained industry Analysts and Consultants, which advises and assists customers in meeting their full service market researchand consulting requirements.

Related Reports

India Stem Cell Market Forecast & Opportunities, 2020

India Infertility Treatments Market Forecast & Opportunities, 2020

Global Tissue Engineered Medical Device Market Forecast & Opportunities, 2020

Disclaimer

The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation ismade that it is timely, accurate or complete. Pharmaion Consultants has taken due care and caution in compilation of data as this has beenobtained from various sources including which it considers reliable and first hand. However, Pharmaion Consultants does not guarantee theaccuracy, adequacy or completeness of any information and it is not responsible for any errors or omissions or for the results obtained from theuse of such information and especially states that it has no financial liability whatsoever to the subscribers / users of this report. Theinformation herein, together with all estimates and forecasts, can change without notice. All the figures provided in this document are indicativeof relative market size and are strictly for client’s internal consumption. Usage of the same for purpose other than internal will require priorapproval of Pharmaion Consultants.

ASIA PACIFIC

Pharmaion Consultants Pvt. Ltd.

A – 51, Sector 57, Noida, National Capital Region,

India - 201301

[email protected]

+91 - 120 - 452 3900

www.pharmaion.com